IFNG and cancer: Second, cancer cells can acquire mutations in the IFNγ signaling pathway that hinder their ability to respond to IFNγ, otherwise known as acquired resistance (Pardoll, 2012; Benci et al, 2016; Gao et al, 2016; Manguso et al, 2017; Shin et al, 2017; Sucker et al, 2017).